Protein Is Identified As An Antigen, E.g., Immunogenic Carriers, Etc. Patents (Class 530/403)
-
Publication number: 20090118475Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.Type: ApplicationFiled: December 30, 2008Publication date: May 7, 2009Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7527798Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.Type: GrantFiled: January 14, 2004Date of Patent: May 5, 2009Assignee: The Wistar InstituteInventors: Walter Gerhard, Laslo Otvos
-
Patent number: 7527797Abstract: The invention pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present invention also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: September 1, 2000Date of Patent: May 5, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Publication number: 20090110692Abstract: Applicants have produced and isolated water soluble complexes of endotoxin and modified MD-2.Type: ApplicationFiled: August 29, 2008Publication date: April 30, 2009Inventor: Jerrold P. Weiss
-
Patent number: 7521202Abstract: The field of the invention relates in general to at least one method and apparatus for the production of soluble MHC antigens and more particularly, but not by way of limitation, to at least one method and apparatus for the production of soluble Class I and II HLA molecules. The field of the invention also includes such produced soluble Class I and II HLA molecules and their use. According to the methodology of the present invention, the soluble Class I and II HLA molecules can be produced from either gDNA or cDNA starting material.Type: GrantFiled: April 4, 2005Date of Patent: April 21, 2009Assignee: The Board of Regents of the University of OklahomaInventors: William H. Hildebrand, Kiley R. Prilliman
-
Publication number: 20090081248Abstract: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest.Type: ApplicationFiled: June 23, 2008Publication date: March 26, 2009Inventors: Yvonne Paterson, Paulo Cesar Maciag
-
Publication number: 20090069500Abstract: This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.Type: ApplicationFiled: January 22, 2004Publication date: March 12, 2009Applicant: Enzo Life Sciences, Inc., c/o Enzo Biochem, Inc.Inventors: Jannis G. Stavrianopoulos, Elazar Rabbani
-
Publication number: 20090068234Abstract: The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3?/CCL20 or ?-defensin mDF2?. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.Type: ApplicationFiled: September 3, 2007Publication date: March 12, 2009Applicant: Government of the US, as represented by the Secretary, Department of Health and Human ServicesInventors: Arya Biragyn, Dan Longo, Igor Espinoza-Delgado
-
Publication number: 20090068211Abstract: Described herein are immunogenically-enhanced polypeptides, such as KSHV LANA1 polypeptides, related methods of eliciting an immune response to the polypeptides and related nucleotide sequences. Also described herein are novel polypeptides capable of inhibiting degradation and/or retarding synthesis of a protein when attached to or incorporated within that protein along with related methods and nucleotide sequences.Type: ApplicationFiled: August 14, 2008Publication date: March 12, 2009Inventors: YUAN CHANG, PATRICK S. MOORE
-
Publication number: 20090068635Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.Type: ApplicationFiled: September 6, 2007Publication date: March 12, 2009Inventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
-
Patent number: 7501125Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.Type: GrantFiled: July 1, 2004Date of Patent: March 10, 2009Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of TechnologyInventors: Qian Huang, Joan F. L. Richmond, Bryan K. Cho, Deborah Pallister, Jianzhu Chen, Herman N. Eisen, Richard A. Young
-
Publication number: 20090053821Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.Type: ApplicationFiled: October 16, 2008Publication date: February 26, 2009Applicant: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
-
Patent number: 7488608Abstract: Methods and compositions are disclosed for reducing non-specific binding in a binding assay for the determination of an analyte in a sample where one of the reagents for conducting the binding assay comprises a solid support comprising a polysaccharide. The method comprises including in an assay medium for conducting the binding assay a soluble compound comprising a protein linked to a polysaccharide. Also disclosed are methods and compositions for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The methods include as reagents a solid support comprising a polysaccharide and a soluble compound comprising a protein linked to a polysaccharide.Type: GrantFiled: January 3, 2007Date of Patent: February 10, 2009Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Zhu Teng, Jeffrey L. Moore, Alan R. Craig, Gary Hickey, Carsten Schelp, Tie Quan Wei
-
Publication number: 20090035259Abstract: The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.Type: ApplicationFiled: June 27, 2008Publication date: February 5, 2009Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventor: James B. Dale
-
Patent number: 7482437Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.Type: GrantFiled: February 2, 2007Date of Patent: January 27, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Richard Terry Root, Mitali Ghoshal, Erasmus Huber, Herbert W. Von Der Eltz, Sigrun Metz, Peter Kern
-
Publication number: 20090022762Abstract: Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs.Type: ApplicationFiled: April 30, 2007Publication date: January 22, 2009Applicant: Techno Vax, Inc.Inventors: Jose M. Galarza, Demetrius Matassov
-
Patent number: 7473535Abstract: The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention.Type: GrantFiled: August 20, 2002Date of Patent: January 6, 2009Assignees: The Institute for Systems Biology, University of WashingtonInventors: Rudolf H. Aebersold, Patricia Q. Bottari, Michael H. Gelb, Frantisek Turecek
-
Publication number: 20090004670Abstract: Embodiments of the invention relate to SEF nanoparticles with increased fluorescence, methods of making SEF nanoparticles, and their application in various bioassays for the detection of target bioanalytes. One embodiment includes the SEF nanoparticle itself, a second embodiment includes the fabrication of SEF nanoparticles, a third embodiment includes methods of using SEF nanoparticles in biodetection assays. A final embodiment includes kits to be used in the fabrication of SEF nanoparticles.Type: ApplicationFiled: June 29, 2007Publication date: January 1, 2009Inventors: Jingwu Zhang, David J. Liu
-
Publication number: 20080305122Abstract: Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide.Type: ApplicationFiled: February 16, 2007Publication date: December 11, 2008Inventors: Robert E. Humphreys, Minzhen Xu
-
Patent number: 7459281Abstract: Novel conjugates of docetaxel and novel docetaxel immunogens derived from the 7 and 10 positions of docetaxel and monoclonal antibodies generated by these docetaxel linked immunogens are useful in immunoassays for the quantification and monitoring of docetaxel in biological fluids.Type: GrantFiled: March 20, 2006Date of Patent: December 2, 2008Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Gregory Drake Lundell, Mahmoud Ahmed ElSohly, Waseem Gul
-
Publication number: 20080286228Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: ApplicationFiled: April 6, 2007Publication date: November 20, 2008Inventors: Stefano R. Tarantolo, Anthony A. Floreani, Ralph J. Hauke, John D. Jackson, Sam D. Sanderson, Art J. Heires, Sandra Gunselman
-
Patent number: 7452982Abstract: The invention relates to an immunogenic complex comprising at a least one glycoside and at least one lipid, integrated into an iscom complex or matrix, and at least one antigen which antigen is integrated into the iscom complex or coupled on to or mixed with the iscom complex or iscom matrix complex, characterised in that it also comprises at least one enzyme. It also relates to such a complex further comprising at least one peptide which specifically binds to a receptor expressed on a cell capable of antigen presentation, which cell expresses MHC Class I or Class II and to compositions comprising the complexes.Type: GrantFiled: October 1, 2001Date of Patent: November 18, 2008Assignee: Arexis ABInventors: Nils Lycke, Kristian Dalsgaard, Allan Mc Mowat, Bjorn Lowenadler, Peter Kaastrup
-
Patent number: 7452971Abstract: The present invention provides methods to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS). The invention also provides ITs and cytokines which have been mutated to lack amino acid sequences which induce VLS.Type: GrantFiled: October 31, 2005Date of Patent: November 18, 2008Assignee: Board of Regents, The University of Texas SystemInventors: Ellen S. Vitetta, Victor F. Ghetie, Joan E. Smallshaw, Roxana G. Baluna
-
Patent number: 7449549Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: July 11, 2002Date of Patent: November 11, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Publication number: 20080260768Abstract: Protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.Type: ApplicationFiled: April 18, 2007Publication date: October 23, 2008Applicant: Sanofi Pasteur LimitedInventors: Christophe Francois Guy Gilbert, Philip Michael Hansbro
-
Patent number: 7439335Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4+ T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.Type: GrantFiled: April 8, 2004Date of Patent: October 21, 2008Assignee: The Scripps Research InstituteInventors: Susan R. Webb, Ola Winqvist, Lars Karlsson, Michael R. Jackson, Per A. Peterson
-
Patent number: 7429640Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 14, 2002Date of Patent: September 30, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Patent number: 7429458Abstract: Bioelastomers are disclosed for use in methods of binding compounds including immunoassay methods, in biosensors and methods or regenerating biosensors, and in methods for targeting the delivery of a compound to a particular location within an animal subjects. In general, the bioelastomer is conjugated to a binding compound, which is in turn used to bind a compound of interest. For targeted compound delivery, the bioelastomer is conjugated to the compound to be delivered.Type: GrantFiled: July 23, 2002Date of Patent: September 30, 2008Assignee: Duke UniversityInventor: Ashutosh Chilkoti
-
Publication number: 20080220008Abstract: Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.Type: ApplicationFiled: August 17, 2005Publication date: September 11, 2008Applicants: INSTITUT GUSTAVE ROUSSY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Martial Renard, Marianne Mangeney, Thierry Heidmann
-
Patent number: 7423131Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: October 6, 2006Date of Patent: September 9, 2008Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 7420043Abstract: The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.Type: GrantFiled: December 10, 2003Date of Patent: September 2, 2008Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald Sigler, Anlong Ouyang
-
Publication number: 20080206271Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.Type: ApplicationFiled: November 30, 2007Publication date: August 28, 2008Applicants: HEALTHBANKS BIOTECH Co., Ltd., ANIMAL TECHNOLOGY INSTITUTE TAIWANInventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Patent number: 7417115Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 14, 2002Date of Patent: August 26, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Publication number: 20080193473Abstract: The present invention concerns a novel method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNF? and a carrier protein, the method steps of which are disclosed in the specification.Type: ApplicationFiled: May 24, 2006Publication date: August 14, 2008Applicant: NEOVACSInventors: Daniel Zagury, Helene Le Buanec
-
Patent number: 7408044Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.Type: GrantFiled: April 1, 2004Date of Patent: August 5, 2008Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Thierry Baussant, Jean-François Haeuw, Thien Ngoc Nguyen
-
Patent number: 7405320Abstract: Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.Type: GrantFiled: February 11, 2004Date of Patent: July 29, 2008Assignee: Immunomedics, Inc.Inventors: William J. McBride, David M. Goldenberg, Carl Noren, Hans J. Hansen
-
Patent number: 7405279Abstract: Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.Type: GrantFiled: June 3, 2005Date of Patent: July 29, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Yi Wang, John Mueller, Louis A. Matis
-
Patent number: 7402315Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: February 20, 2007Date of Patent: July 22, 2008Assignees: Common Services Agency, Murex Diagnostics LimitedInventors: Peter Simmonds, Peng L. Yap, Ian H. Pike
-
Publication number: 20080171061Abstract: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.Type: ApplicationFiled: July 19, 2007Publication date: July 17, 2008Inventors: Douglas Nixon, Keith Garrison, Duncan Meiklejohn, Mario Ostrowski, R. Bradley Jones, Ashish Agrawal, Jack Lenz, Seth Rakoff-Nahoum, Frederick M. Hecht
-
Patent number: 7399645Abstract: The invention pertains to bioconjugation systems comprising sterically constrained cis-diols and borates.Type: GrantFiled: May 11, 2005Date of Patent: July 15, 2008Assignee: Applera CorporationInventors: Ricky F. Baggio, Alison L. Sparks, Rouh-Rong Juo, Jaime E. Arenas
-
Patent number: 7399838Abstract: A recombinant polypeptide and nucleic acid constructs capable of expressing the recombinant polypeptide are provided. The recombinant polypeptide comprises a chimeric polypeptide including an antigenic peptide being capable of binding a human MHC class I, a functional human ?-2 microglobulin and a functional human MHC class I heavy chain.Type: GrantFiled: February 13, 2002Date of Patent: July 15, 2008Assignee: Technion Research & Development Foundation Ltd.Inventor: Yoram Reiter
-
Publication number: 20080166360Abstract: A purified nucleic acid molecule comprising a nucleotide sequence coding for allergen Dac g 5 having amino acid sequence SEQ ID NO. 2, a derivative or a fragment thereof.Type: ApplicationFiled: September 13, 2007Publication date: July 10, 2008Applicants: Seita Groupe Altadis, a French corporation, Stallergenes, a French corporationInventors: Ronald van Ree, Erica Van Oort, Caroline Bonneau, Loic Faye, Veronique Gomord
-
Publication number: 20080161537Abstract: Provided herein are methods for introducing fluorine atom onto a biomolecule comprising: (i) providing a linker comprising a thiol-reactive terminus and an azido/alkyne-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a biomolecule comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting the azido/alkyne-reactive terminus of the linker with a fluorine-substituted azide or alkyne respectively. Also provided are compositions and method of synthesis of bifunctional linkers and bioconjugates as well as radio-diagnostic agents comprising fluorine-labeled biomolecules.Type: ApplicationFiled: December 20, 2007Publication date: July 3, 2008Applicant: GENERAL ELECTRIC COMPANYInventors: Omayra Liz Padilla De Jesus, Ernest William Kovacs, Matthias Eberhard Glaser, Erik Arstad, Faisal Ahmed Syud
-
Publication number: 20080153082Abstract: This invention provides polyanionic polymer conjugates containing non-nucleotide polyanionic polymers that are useful in detecting target analytes such as proteins or small molecules. The invention also provides nanoparticles bound to polyanionic polymer conjugates and methods of preparation and use thereof. The polyanionic polymer conjugates have the formula: L-O—[PO2—O-Z-O]n—PO2—O—X wherein n ranges from 1 to 200; L represents a moiety comprising a functional group for attaching the polyanion polymer to the nanoparticle surface; Z represents a bridging group, and X represents Q, X? or -Q-X?, wherein Q represents a functional group for attaching a recognition probe to the polyanion polymer, and X? represents a recognition probe.Type: ApplicationFiled: August 6, 2007Publication date: June 26, 2008Applicant: Nanosphere, Inc.Inventors: James J. Storhoff, Robert L. Letsinger, Susan R. Hagenow
-
Patent number: 7390878Abstract: The present invention is directed to novel polypeptides having sequence similarity to trypsinogen and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 14, 2002Date of Patent: June 24, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Publication number: 20080145378Abstract: The present invention concerns multimeric proteinaceous molecules comprising at least two members that bind each other via a region of noncovalent interaction, wherein a first of said members comprises a conditionally reactive group that, when activated, cleaves a covalent bond within said first member. Cleavage of the covalent bond results in a reduction in the binding strength with which the at least two members bind to each other via said region of noncovalent interaction. The reduction in the binding strength can result in the separation of the members under mild conditions.Type: ApplicationFiled: January 25, 2006Publication date: June 19, 2008Inventors: Huib Ovaa, Antonius Nicolaas Maria Schumacher
-
Patent number: 7388073Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: July 12, 2002Date of Patent: June 17, 2008Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
-
Patent number: 7388072Abstract: The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.Type: GrantFiled: May 23, 2003Date of Patent: June 17, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
-
Publication number: 20080138892Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.Type: ApplicationFiled: December 5, 2006Publication date: June 12, 2008Applicant: Vaccine Research Institute of San DiegoInventors: David R. Milich, Jean-Noel Billaud
-
Patent number: RE40596Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.Type: GrantFiled: February 6, 2007Date of Patent: December 2, 2008Assignee: Novartis AGInventors: Richard Sedrani, Valerie Quesniaux Ryffel